Bayer and Zydus Cadila sign India deal
pharmafile | February 4, 2011 | News story | Sales and Marketing | Bayer, India, Indian pharmaceutical industry, Zydus Cadila
Bayer HealthCare and the Indian company Zydus Cadila have signed a deal to form a new joint venture.
A new 50/50 owned company called Bayer Zydus Pharma will be established, focused around the marketing and sales of the two companies’ portfolios.
Bayer says the joint venture is a crucial element of the company’s strategy to build a stronger presence in the emerging markets.
Dr Jörg Reinhardt, chief executive of Bayer HealthCare, said: “With this step, we aim to significantly accelerate our capabilities to better serve the fast growing Indian market. We believe that the joint venture between Bayer HealthCare and Zydus Cadila will provide a win-win situation for both partners.
“We expect to leverage on the strengths of the joint venture such as the optimised product portfolio and the distribution capabilities to enhance the launch of new products and the sales of existing brands.”
Both partners will bring into Bayer Zydus Pharma a complementary product portfolio and specialised sales forces in women’s healthcare, diagnostic imaging, and general medicines as well as oncology.
The company, to be headquartered in Mumbai, India, will combine Zydus Cadila’s Indian marketing and sales experience, as well as distribution and industry network with Bayer HealthCare’s expertise in commercialising novel products, along with its administration and sales processes.
A total of 600 employees, coming from both Bayer HealthCare as well as from Zydus Cadila, will form the Bayer Zydus Pharma operations.
Bayer Zydus Pharma will focus on women’s healthcare, diagnostic imaging, cardiovascular diseases, diabetes treatments, and oncology.
Bayer Zydus Pharma’s future product portfolio will not only include in-licensed and originator brands, but also patented pharmaceuticals from Bayer HealthCare’s pipeline.
The joint venture’s combined portfolio will include brands such as Glucobay, Xarelto, Nexavar and Yaz/Yasmin from Bayer HealthCare, as well as products currently marketed by Zydus Cadila such as Euglim, Progynova and Ultravist.
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …
Bayer and Evotec to collaborate on precision cardiology
Bayer and Evotec have announced that they have updated the focus of their collaboration to …
